Yuhan Corporation announced on Thursday that it will receive a 30 million USD milestone payment for the European commercialization of Lazertinib, its non-small cell lung cancer treatment licensed to Janssen Biotech. This payment is part of a series of milestones tied to the European launch of Lazertinib in combination with Janssen’s Amivantamab.
To date, Yuhan Corporation has amassed 300 million USD in total milestone payments for Lazertinib (marketed as Leclaza in South Korea), including the initial signing fee.
The milestone payments break down as follows: △ Initial signing fee (November 2018, 50 million USD) △ Combination development progress (April 2020, 35 million USD) △ Phase 3 combination dosing initiation (November 2020, 65 million USD) △ U.S. market launch (September 2024, 60 million USD) △ Japanese market launch (May 2025, 15 million USD) △ Chinese market launch (October 2025, 45 million USD) △ European market launch (May 2026, 30 million USD).
Yuhan Corporation is set to receive a total of 950 million USD in milestone payments, including the initial fee, with about one-third already collected. The company began receiving sales royalties based on combination therapy prescriptions in 2024, and the recent European launch is expected to boost global sales and royalty income.
Lazertinib has expanded its reach across four continents: Asia, Europe, the Americas, and Oceania. Notably, it was designated as the preferred first-line treatment (Category 1) for EGFR-mutated non-small cell lung cancer in the National Comprehensive Cancer Network (NCCN) guidelines last November, cementing its status as a globally recognized standard of care.
This year marks Yuhan Corporation’s centennial anniversary. The company aims to build on its century-long legacy of trust by embracing new responsibilities and fostering innovation, with the goal of evolving into a global leader in healthcare that improves lives not just in South Korea, but worldwide.
A Yuhan Corporation spokesperson stated that they’re committed to honoring Yuhan’s legacy by completing a century of innovation and ushering in a new era of global health through groundbreaking drug development. The mission is to create a healthier, happier world for future generations.